证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230601 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2023 年 5 月 30 日、2023 年 6 月 1 日、2023 年 6 月 2 日 地点 腾讯会议 参与单位名称 （排名不分先 后） 国金证券：李润兰 中银证券：周海涛 上银基金：纪晓天 玄元投资：廖仕超 恒生前海：鲁娜 申万菱信：杨扬 盘京投资：温旭鸾 建投资管：彭国宇 中银基金：王方舟、郑宁 淳厚基金：严定安、张卓颖 银华基金：陈子浩、郭思捷、焦巍 金信基金：赵浩然、谭智汨 平安基金：王文豪、张淼、刘杰 上市公司接待 人员姓名 董事会秘书兼副总裁杨永兴先生，证券事务代表李韵妮女士，证券事务专 员钟欣昊先生。 投资者关系活 动主要内容介 绍 公司经营情况介绍： 2022 年，面对复杂多变的宏观环境与诸多的困难挑战，公司在坚持发 展战略的同时积极应对市场变化，聚焦于引进优秀人才、完善营销网络、 推广高端新品、优化研发力量，确保年度经营计划有序开展。 尽管公司遭遇各种不利因素 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230502 特定对象调研 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 时间 2023 年 5 月 23 至 2023 年 5 月 25 日 地点 珠海、上海、腾讯会议 参与单位名称 光大证券：张杰 博时基金：张涵 （排名不分先 安信基金：徐衍鹏 国联安基金：赵子淇 后） 平安资产：林启姜 天弘基金：郭相博 华安基金：于嘉轩 金鹰基金：张天问 华宝基金：易镜明、张金涛、薄玉、郑 中国人保资产：蔡春根、马善 英亮、齐震、 尧、华旭桥 农银汇理基金：凌晨、李蕾、梦圆 上市公司接待 人员姓名 董事会秘书兼副总裁杨永兴先生，证券事务专员钟欣昊先生。 公司经营情况介绍： 投资者关系活 2022 年，面对复杂多变的宏观环境与诸多的困难挑战，公司在坚持发 动主要内容介 展战略的同时积极应对市场变化，聚焦于引进优秀人才、完善营销网络、 绍 推广高端新品、优化研发力量，确保年度经营计划有序开展。 尽管公司遭遇各种不利因素影响，但通过多方努力，尤其是产品力的 | --- | | ...

广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230501 | |  特定对象调研 | | 分析师会议 | | | --- | --- | --- | --- | --- | | 投资者关系活 | 媒体采访 | | 业绩说明会 | | | 动类别 | 新闻发布会 | | 路演活动 | | | | 现场参观 | | | | | | 其他 | | | | | 时间 | 2023 年 5 月 10 | 日、2023 | 年 5 月 11 日 | | | 地点 | 上海、深圳 | | | | | 参与单位名称 | 申万宏源：陈烨远、陶涛、王林森 | | | 国盛证券：殷一凡 | | （排名不分先 | 世域投资：李巍 | | | 鼎锋资产：刘硕 | | 后） | 嘉实基金：孙晓晖 | | | 睿远基金：赵培森 | | | 汇添富基金：谢杰 | | | 健顺投资：王坚 | | | 仙人掌私募：熊龙启 | | | 宝弘景资产：张乐 | | | 磐耀资产：孙智超 | | | 新伯霖私募：何志俊 | | | 国鸣投资：李长天 | | | 安信资管：刘亚洲 | | | 富荣基金：杨皓童 | | | ...

广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230402 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2023 年 4 月 28 日 地点 价值在线（https://www.ir-online.cn/） 参与单位名称 线上参与公司 2022 年度业绩网上说明会的全体投资者 上市公司接待 人员姓名 董事长兼总裁 燕金元先生 独立董事 杨振新先生 保荐代表人 胡凤兴先生 财务总监 许薇女士 董事会秘书兼副总裁 杨永兴先生 投资者关系活 动主要内容介 绍 1、请简单介绍一下公司去年及今年一季度的经营情况，谢谢！ 答：2022 年，面对复杂多变的宏观环境与诸多的困难挑战，在公司管 理层和全体员工的共同努力下，公司经营情况总体保持稳定，各项财务指 标较为健康：2022年，公司实现营业收入118,369.97万元，同比增长8.49%； 实现归属于上市公司股东的净利润为 2,199.80 万元，同比下降 65.52%。 2022 年公司净利润下降除了受物流成本上升、原材料价格上涨等负面影 响外，也是公司为保持持续竞争力，着眼未来进行战略 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 344,565,792.16, representing an increase of 18.09% compared to CNY 291,794,237.98 in the same period last year[5] - Net profit attributable to shareholders reached CNY 27,162,153.53, a significant increase of 94.75% from CNY 13,947,291.98 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,081,480.62, up 80.71% from CNY 12,772,332.15 in the previous year[5] - Basic earnings per share rose to CNY 0.1545, an increase of 83.06% compared to CNY 0.0844 in the same quarter last year[5] - Operating profit surged by 117.53% to ¥36,002,392.50 driven by increased product sales revenue and gross margin growth[10] - Net profit increased by 97.80% to ¥28,305,836.21 attributed to higher product sales revenue and gross margin[11] - The company reported a total comprehensive income of ¥28,710,677.12, compared to ¥13,520,521.78 in the same quarter last year[21] Assets and Liabilities - The company's total assets increased by 6.00% to CNY 2,585,169,605.44 from CNY 2,438,861,738.92 at the end of the previous year[5] - As of March 31, 2023, the total assets of Guangdong Baolait Medical Technology Co., Ltd. amounted to CNY 2,585,169,605.44, an increase from CNY 2,438,861,738.92 at the beginning of the year, reflecting a growth of approximately 6.0%[17] - Total current liabilities increased to CNY 673,808,834.57 from CNY 603,389,790.05, marking an increase of about 11.6%[18] - The company's total equity as of March 31, 2023, was CNY 1,536,095,250.43, up from CNY 1,502,442,989.80, showing a growth of about 2.2%[18] - The total liabilities of the company increased to CNY 1,049,074,355.01 from CNY 936,418,749.12, reflecting an increase of approximately 12.0%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -63,981,560.58, a decline of 1,075.54% from CNY 6,558,556.06 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥63,981,560.58, compared to a net inflow of ¥6,558,556.06 in Q1 2022[23] - The net cash flow from financing activities was ¥130,778,416.32, a decrease from ¥514,743,668.08 in the previous year[24] - The total cash and cash equivalents at the end of the period amounted to ¥434,543,141.97, down from ¥740,565,884.82 year-over-year[24] - The net increase in cash and cash equivalents for the quarter was ¥32,130,753.01, significantly lower than ¥473,952,206.85 in the previous year[24] Research and Development - Research and development expenses increased by 33.29% to CNY 24,786,031.00 from CNY 18,595,887.26 year-on-year[9] - Research and development expenses grew by 33.29% to ¥24,786,031.00 reflecting increased investment in R&D[10] Investments and Income - The company reported a significant increase in investment income, which rose to CNY 2,663,044.36, compared to a loss of CNY -69,780.89 in the previous year, marking a 3,916.29% change[9] - Total revenue from government subsidies rose by 369.07% to ¥12,644,802.89 during the reporting period[10] - The company recorded a significant increase in other income to ¥12,644,802.89, compared to ¥2,695,742.22 in Q1 2022[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,305[13] - Earnings per share increased by 83.06% to ¥0.1545 due to the growth in net profit attributable to shareholders[11] - The total equity attributable to shareholders of the parent company increased to ¥1,445,011,388.04, compared to ¥1,416,280,945.57 in the previous year[19] Inventory and Receivables - Accounts receivable decreased by 44.84% to ¥3,869,844.66 due to the maturity of bank acceptance bills during the reporting period[10] - Prepayments increased by 33.89% to ¥41,889,070.78 as the company increased advance payments for sales inventory[10] - Inventory rose by 52.78% to ¥306,438,713.62 due to increased procurement for sales inventory[10] Borrowings - The company received cash from bank loans amounting to ¥165,300,000.00, a 1036.07% increase compared to the previous period[11] - Short-term borrowings rose to CNY 209,996,000.00, compared to CNY 132,640,000.00 at the beginning of the year, reflecting an increase of approximately 58.2%[18] - The long-term borrowings increased to CNY 107,520,000.00 from CNY 68,520,000.00, representing a rise of approximately 56.9%[18] - The company’s cash received from borrowings was ¥165,300,000.00, compared to ¥14,550,125.00 in the previous year[24] Audit Information - The company did not conduct an audit for the first quarter report[25]

Financial Performance - In 2022, the company's revenue increased year-on-year despite various adverse factors, but net profit attributable to shareholders decreased due to rising logistics costs, raw material prices, and increased sales and R&D expenses [4]. - The company's operating revenue for 2022 was approximately ¥1.18 billion, an increase of 8.49% compared to ¥1.09 billion in 2021 [23]. - The net profit attributable to shareholders decreased by 65.52% to approximately ¥22 million in 2022 from ¥63.79 million in 2021 [23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥6.66 million, a decline of 115.04% compared to ¥44.24 million in 2021 [23]. - The cash flow from operating activities increased by 74.56% to approximately ¥140.72 million in 2022 from ¥80.61 million in 2021 [23]. - The total assets at the end of 2022 were approximately ¥2.44 billion, a growth of 41.83% from ¥1.72 billion at the end of 2021 [23]. - The net assets attributable to shareholders increased by 58.44% to approximately ¥1.42 billion at the end of 2022 from ¥893.89 million at the end of 2021 [23]. - The company reported a basic earnings per share of ¥0.1273, down 70.85% from ¥0.4367 in 2021 [23]. - The company received government subsidies amounting to approximately ¥26.24 million in 2022, compared to ¥21.69 million in 2021 [28]. Market Position and Strategy - The company is positioned as a leader in critical care and nephrology, focusing on domestic substitution for imported medical devices and hospital upgrades [6]. - The company aims to enhance product competitiveness and brand influence by increasing R&D investment and optimizing supply chain management, production capacity, and logistics [6]. - The company is committed to leveraging its multi-base layout to achieve growth in its main business and improve efficiency and effectiveness [6]. - The report highlights the absence of major risks in the company's ongoing operations, ensuring a stable outlook for future development [6]. - The company plans to enhance operational management and leverage opportunities in the domestic medical device market in 2023 [55]. - The company aims to strengthen its product competitiveness and brand influence through increased R&D efforts and supply chain optimization [55]. - The company aims to capitalize on the domestic medical device replacement of imports and hospital upgrades as key growth opportunities [65]. Research and Development - The company invested 90.63 million yuan in R&D, a year-on-year increase of 17.04% [56]. - The company holds 45 authorized invention patents, 254 utility model patents, and 25 design patents as of December 31, 2022 [56]. - The company has established a comprehensive product development process to ensure the conversion of technological innovations into results [51]. - The company has developed multiple high-tech products, including the Q series multi-parameter monitors and dialysis machines, recognized as high-tech products in Guangdong Province [57]. - The company continues to invest in research and development to innovate and enhance its product line [59]. - The company is advancing the development of new products, including the G series monitors and CRRT devices, to meet market demands [71]. - The company has a strong focus on R&D, with 51 new patents including 5 invention patents and 39 utility model patents added in the reporting period [57]. Product Development and Innovation - The company has launched several new products, including the P series patient monitors (P12, P15, P18, P22) and transport monitor (P1), which received medical device registration certificates from regulatory authorities [66]. - The company has developed multiple software copyrights for its medical devices, enhancing its technological capabilities in patient monitoring and dialysis [59]. - The company is focusing on expanding its product line in patient monitoring and dialysis, with several products receiving regulatory approval in recent years, indicating a strong commitment to innovation and market presence [98]. - The company has introduced a new dialysis fluid filter, approved in May 2019, which utilizes hollow fiber membrane technology to remove toxins and bacteria, requiring replacement after 900 hours or 160 treatments [98]. - The company is expanding its product line with various blood dialysis solutions, including AH01-Ⅲ and AH04-Ⅰ, with packaging sizes ranging from 5L to 12.5L [103]. Regulatory Compliance and Certifications - The company holds 21 FDA510(k) market access licenses as of December 31, 2022, indicating a strong regulatory compliance and product approval status in the U.S. market [105]. - The company has obtained 2 CE certificates in the EU, with one certificate valid until April 15, 2023, and the other until May 26, 2024 [104]. - The company has received regulatory approval for multiple medical devices, including the wireless body temperature monitoring system WT1, which is suitable for continuous measurement of human body temperature [101]. - The company has received regulatory approval for multiple blood dialysis products, including AH01-Ⅰ and AH02-Ⅳ, with expected market availability until June 2027 [103]. Corporate Governance and Management - The company is committed to improving its corporate governance structure in accordance with relevant laws and regulations, enhancing operational transparency and accountability [161]. - The company has established a performance evaluation and incentive system for its directors, supervisors, and senior management, ensuring that compensation is linked to actual performance [165]. - The board of directors consists of 9 members, including 3 independent directors, and has held 10 meetings during the reporting period [163]. - The company has maintained complete independence from its controlling shareholders in terms of business, personnel, assets, and financial operations [166]. - The company has a transparent and fair performance evaluation mechanism for its management, with no violations reported during the period [165]. Social Responsibility and Community Engagement - The company donated CNY 100,000 to support rural revitalization projects and provided medical equipment to local healthcare institutions, reflecting its commitment to social responsibility [82]. - The company has established a scientific assessment and incentive system to maximize talent potential and promote organizational innovation [195]. - The company conducted training programs aimed at enhancing employee skills and fostering a shared corporate culture [196]. Future Outlook and Growth Plans - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20% [178]. - The company is exploring potential acquisitions of smaller medical technology firms to enhance its product portfolio and market reach [178]. - The company aims to enhance its R&D capabilities and product competitiveness by investing in innovation and protecting its intellectual property [140]. - The company plans to focus on health monitoring and blood purification sectors in 2023, aiming for a doubling of sales volume for dialysis devices and related products annually [140].

债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 证券代码：300246 证券简称：宝莱特 公告编号：2023-029 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 广东宝莱特医用科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 19 日在巨潮资讯网上披露了《2022 年年度报告》及其摘要。为便于广大投资者 更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 04 月 28 日（星期五）15:00-17:00 在"价值在线"（www.ir-online.cn）举办广东宝莱 特医用科技股份有限公司 2022 年度业绩网上说明会，与投资者进行沟通和交流， 广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 28 日（星期五）15:00-17:00 会议召开时间：2023 年 04 月 28 日（星期五）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-onl ...